Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Background Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate‐to‐severe plaque psoriasis. Real‐world evidence on the effectiveness and safety of tildrakizumab is limited. Objectives To assess the effective...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2023-12, Vol.37 (12), p.2517-2525
Hauptverfasser:	Berenguer‐Ruiz, Sonsoles, Aparicio‐Domínguez, Mario, Herranz‐Pinto, Pedro, Ruíz‐Villaverde, Ricardo, López‐Ferrer, Anna, Santos‐Juanes, Jorge, Rodríguez Fernández‐Freire, Lourdes, Hospital‐Gil, Mercedes, Arias‐Santiago, Salvador, Carretero‐Hernández, Gregorio, Mateu‐Puchades, Almudena, Ferran, Marta, Alcázar, Elena, Santos‐Alarcón, Sergio, Garcia‐Latasa de Aranibar, Francisco Javier, Belinchón‐Romero, Isabel, González‐Cantero, Álvaro, Ruíz‐Genao, Diana, Eiris‐Salvado, Noemí, Rocamora‐Durán, Vicenç, Rivera‐Diaz, Raquel, Cueva, Pablo, Daudén, Esteban, Salgado‐Boquete, Laura, Llamas‐Velasco, Mar
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!